Research and standardization in Alzheimer's trials: Reaching international consensus

被引：17

作者：

Carrillo, Maria C. ^{[1
]}

Rowe, Christopher C. ^{[2
]}

Szoeke, Cassandra ^{[3
]}

Masters, Colin L. ^{[4
]}

Ames, David ^{[3
,7
]}

O'Meara, Tim ^{[5
]}

Macaulay, S. Lance ^{[5
]}

Milner, Andrew ^{[6
]}

Ellis, Kathryn A. ^{[7
]}

Maruff, Paul ^{[4
]}

Rainey-Smith, Stephanie R. ^{[8
]}

Martins, Ralph N. ^{[8
]}

Bain, Lisa J.

Head, Richard J. ^{[9
]}

机构：

[1] Alzheimers Assoc, Chicago, IL USA

[2] Austin Hlth, Heidelberg, Vic 3084, Australia

[3] Natl Ageing Res Inst, Parkville, Vic 3052, Australia

[4] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3010, Australia

[5] CSIRO Preventat Hlth Flagship Mat Sci & Engn, Parkville, Vic 3052, Australia

[6] Neurosci Victoria, Carlton, Vic 3053, Australia

[7] Univ Melbourne, Dept Psychiat, Acad Unit Psychiat Old Age, Parkville, Vic 3010, Australia

[8] Edith Cowan Univ, Joondalup, WA 6027, Australia

[9] CSIRO Preventat Hlth Flagship, Adelaide, SA, Australia

来源：

ALZHEIMERS & DEMENTIA | 2013年 / 9卷 / 02期

关键词：

Alzheimer's disease; Diagnosis; Early detection; Biomarkers; Clinical outcomes; Cerebral spinal fluid; Amyloid imaging; Magnetic resonance imaging; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; MEDITERRANEAN DIET; PLASMA BIOMARKERS; CLINICAL-TRIALS; DISEASE; PET; RECOMMENDATIONS; PREVENTION; DIAGNOSIS;

D O I：

10.1016/j.jalz.2012.10.006

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide. (c) 2013 The Alzheimer's Association. All rights reserved.

引用

页码：160 / 168

页数：9

共 52 条

[11] Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, Christopher M.
Schneider, Julie A.
Bedell, Barry J.
Beach, Thomas G.
Bilker, Warren B.
Mintun, Mark A.
Pontecorvo, Michael J.
Hefti, Franz
Carpenter, Alan P.
Flitter, Matthew L.
Krautkramer, Michael J.
Kung, Hank F.
Coleman, R. Edward
Doraiswamy, P. Murali
Fleisher, Adam S.
Sabbagh, Marwan N.
Sadowsky, Carl H.
Reiman, P. Eric M.
Zehntner, Simone P.
Skovronsky, Daniel M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03): : 275 - 283
[12] Brain microbleeds and Alzheimer's disease: innocent observation or key player?
Cordonnier, Charlotte
van der Flier, Wiesje M.
[J]. BRAIN, 2011, 134 : 335 - 344
[13] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria
Dubois, Bruno
Feldman, Howard H.
Jacova, Claudia
Dekosky, Steven T.
Barberger-Gateau, Pascale
Cummings, Jeffrey
Delocourte, Andre
Galasko, Douglas
Gauthier, Serge
Jicha, Gregory
Meguro, Kenichi
O'Brien, John
Pasquier, Florence
Robert, Philippe
Rossor, Martin
Solloway, Steven
Stern, Yaakov
Visser, Pieter J.
Scheltens, Philip
[J]. LANCET NEUROLOGY, 2007, 6 (08) : 734 - 746
[14] Adherence to a Mediterranean Diet, Cognitive Decline, and Risk of Dementia
Feart, Catherine
Samieri, Cecilia
Rondeau, Virginie
Amieva, Helene
Portet, Florence
Dartigues, Jean-Francois
Scarmeas, Nikolaos
Barberger-Gateau, Pascale
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (06): : 638 - 648
[15] Harmonization of magnetic resonance-based manual hippocampal segmentation: A mandatory step for wide clinical use
Frisoni, Giovanni B.
Jack, Clifford R.
[J]. ALZHEIMERS & DEMENTIA, 2011, 7 (02) : 171 - 174
[16] The clinical use of structural MRI in Alzheimer disease
Frisoni, Giovanni B.
Fox, Nick C.
Jack, Clifford R., Jr.
Scheltens, Philip
Thompson, Paul M.
[J]. NATURE REVIEWS NEUROLOGY, 2010, 6 (02) : 67 - 77
[17] Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease
Henley, David B.
May, Patrick C.
Dean, Robert A.
Siemers, Eric R.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (10) : 1657 - 1664
[18] Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A.
Lynham, S.
Thambisetty, M.
Causevic, M.
Campbell, J.
Byers, H. L.
Hooper, C.
Rijsdijk, F.
Tabrizi, S. J.
Banner, S.
Shaw, C. E.
Foy, C.
Poppe, M.
Archer, N.
Hamilton, G.
Powell, J.
Brown, R. G.
Sham, P.
Ward, M.
Lovestone, S.
[J]. BRAIN, 2006, 129 : 3042 - 3050
[19] Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials
Isaac, Maria
Vamvakas, Spiros
Abadie, Eric
Jonsson, Bertil
Gispen, Christine
Pani, Luca
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 (11) : 781 - 788
[20] Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, Clifford R., Jr.
Vemuri, Prashanthi
Wiste, Heather J.
Weigand, Stephen D.
Lesnick, Timothy G.
Lowe, Val
Kantarci, Kejal
Bernstein, Matt A.
Senjem, Matthew L.
Gunter, Jeffrey L.
Boeve, Bradley F.
Trojanowski, John Q.
Shaw, Leslie M.
Aisen, Paul S.
Weiner, Michael W.
Petersen, Ronald C.
Knopman, David S.
[J]. ARCHIVES OF NEUROLOGY, 2012, 69 (07) : 856 - 867

← 1 2 3 4 5 6 →